Real-life experience after 3 months with tezepelumab before marketing approval
CONCLUSIONS: In this preliminary real-world experience prior to the official approval of tezepelumab in Spain, this monoclonal antibody showed promising results and suggests its potential as a valuable alternative for the treatment of severe asthma.PMID:38459894 | DOI:10.15586/aei.v52i2.1063 (Source: Allergologia et Immunopathologia)
Source: Allergologia et Immunopathologia - March 9, 2024 Category: Allergy & Immunology Authors: Victoria Villalobos Viol án Beatriz Gonz ález Cano Miguel Ángel Racionero Casero Elo ína González-Mancebo Esther Mohedano Vicente Mar ía Jesús Trujillo Trujillo Mar Gandolfo-Cano Source Type: research
Real-life experience after 3 months with tezepelumab before marketing approval
CONCLUSIONS: In this preliminary real-world experience prior to the official approval of tezepelumab in Spain, this monoclonal antibody showed promising results and suggests its potential as a valuable alternative for the treatment of severe asthma.PMID:38459894 | DOI:10.15586/aei.v52i2.1063 (Source: Allergologia et Immunopathologia)
Source: Allergologia et Immunopathologia - March 9, 2024 Category: Allergy & Immunology Authors: Victoria Villalobos Viol án Beatriz Gonz ález Cano Miguel Ángel Racionero Casero Elo ína González-Mancebo Esther Mohedano Vicente Mar ía Jesús Trujillo Trujillo Mar Gandolfo-Cano Source Type: research
Real-life experience after 3 months with tezepelumab before marketing approval
CONCLUSIONS: In this preliminary real-world experience prior to the official approval of tezepelumab in Spain, this monoclonal antibody showed promising results and suggests its potential as a valuable alternative for the treatment of severe asthma.PMID:38459894 | DOI:10.15586/aei.v52i2.1063 (Source: Allergologia et Immunopathologia)
Source: Allergologia et Immunopathologia - March 9, 2024 Category: Allergy & Immunology Authors: Victoria Villalobos Viol án Beatriz Gonz ález Cano Miguel Ángel Racionero Casero Elo ína González-Mancebo Esther Mohedano Vicente Mar ía Jesús Trujillo Trujillo Mar Gandolfo-Cano Source Type: research
Real-life experience after 3 months with tezepelumab before marketing approval
CONCLUSIONS: In this preliminary real-world experience prior to the official approval of tezepelumab in Spain, this monoclonal antibody showed promising results and suggests its potential as a valuable alternative for the treatment of severe asthma.PMID:38459894 | DOI:10.15586/aei.v52i2.1063 (Source: Allergologia et Immunopathologia)
Source: Allergologia et Immunopathologia - March 9, 2024 Category: Allergy & Immunology Authors: Victoria Villalobos Viol án Beatriz Gonz ález Cano Miguel Ángel Racionero Casero Elo ína González-Mancebo Esther Mohedano Vicente Mar ía Jesús Trujillo Trujillo Mar Gandolfo-Cano Source Type: research
Real-life experience after 3 months with tezepelumab before marketing approval
CONCLUSIONS: In this preliminary real-world experience prior to the official approval of tezepelumab in Spain, this monoclonal antibody showed promising results and suggests its potential as a valuable alternative for the treatment of severe asthma.PMID:38459894 | DOI:10.15586/aei.v52i2.1063 (Source: Allergologia et Immunopathologia)
Source: Allergologia et Immunopathologia - March 9, 2024 Category: Allergy & Immunology Authors: Victoria Villalobos Viol án Beatriz Gonz ález Cano Miguel Ángel Racionero Casero Elo ína González-Mancebo Esther Mohedano Vicente Mar ía Jesús Trujillo Trujillo Mar Gandolfo-Cano Source Type: research
Real-life experience after 3 months with tezepelumab before marketing approval
CONCLUSIONS: In this preliminary real-world experience prior to the official approval of tezepelumab in Spain, this monoclonal antibody showed promising results and suggests its potential as a valuable alternative for the treatment of severe asthma.PMID:38459894 | DOI:10.15586/aei.v52i2.1063 (Source: Allergologia et Immunopathologia)
Source: Allergologia et Immunopathologia - March 9, 2024 Category: Allergy & Immunology Authors: Victoria Villalobos Viol án Beatriz Gonz ález Cano Miguel Ángel Racionero Casero Elo ína González-Mancebo Esther Mohedano Vicente Mar ía Jesús Trujillo Trujillo Mar Gandolfo-Cano Source Type: research
Real-life experience after 3 months with tezepelumab before marketing approval
CONCLUSIONS: In this preliminary real-world experience prior to the official approval of tezepelumab in Spain, this monoclonal antibody showed promising results and suggests its potential as a valuable alternative for the treatment of severe asthma.PMID:38459894 | DOI:10.15586/aei.v52i2.1063 (Source: Allergologia et Immunopathologia)
Source: Allergologia et Immunopathologia - March 9, 2024 Category: Allergy & Immunology Authors: Victoria Villalobos Viol án Beatriz Gonz ález Cano Miguel Ángel Racionero Casero Elo ína González-Mancebo Esther Mohedano Vicente Mar ía Jesús Trujillo Trujillo Mar Gandolfo-Cano Source Type: research
Real-life experience after 3 months with tezepelumab before marketing approval
CONCLUSIONS: In this preliminary real-world experience prior to the official approval of tezepelumab in Spain, this monoclonal antibody showed promising results and suggests its potential as a valuable alternative for the treatment of severe asthma.PMID:38459894 | DOI:10.15586/aei.v52i2.1063 (Source: Allergologia et Immunopathologia)
Source: Allergologia et Immunopathologia - March 9, 2024 Category: Allergy & Immunology Authors: Victoria Villalobos Viol án Beatriz Gonz ález Cano Miguel Ángel Racionero Casero Elo ína González-Mancebo Esther Mohedano Vicente Mar ía Jesús Trujillo Trujillo Mar Gandolfo-Cano Source Type: research
Real-life experience after 3 months with tezepelumab before marketing approval
CONCLUSIONS: In this preliminary real-world experience prior to the official approval of tezepelumab in Spain, this monoclonal antibody showed promising results and suggests its potential as a valuable alternative for the treatment of severe asthma.PMID:38459894 | DOI:10.15586/aei.v52i2.1063 (Source: Allergologia et Immunopathologia)
Source: Allergologia et Immunopathologia - March 9, 2024 Category: Allergy & Immunology Authors: Victoria Villalobos Viol án Beatriz Gonz ález Cano Miguel Ángel Racionero Casero Elo ína González-Mancebo Esther Mohedano Vicente Mar ía Jesús Trujillo Trujillo Mar Gandolfo-Cano Source Type: research
Real-life experience after 3 months with tezepelumab before marketing approval
CONCLUSIONS: In this preliminary real-world experience prior to the official approval of tezepelumab in Spain, this monoclonal antibody showed promising results and suggests its potential as a valuable alternative for the treatment of severe asthma.PMID:38459894 | DOI:10.15586/aei.v52i2.1063 (Source: Allergologia et Immunopathologia)
Source: Allergologia et Immunopathologia - March 9, 2024 Category: Allergy & Immunology Authors: Victoria Villalobos Viol án Beatriz Gonz ález Cano Miguel Ángel Racionero Casero Elo ína González-Mancebo Esther Mohedano Vicente Mar ía Jesús Trujillo Trujillo Mar Gandolfo-Cano Source Type: research
Real-life experience after 3 months with tezepelumab before marketing approval
CONCLUSIONS: In this preliminary real-world experience prior to the official approval of tezepelumab in Spain, this monoclonal antibody showed promising results and suggests its potential as a valuable alternative for the treatment of severe asthma.PMID:38459894 | DOI:10.15586/aei.v52i2.1063 (Source: Allergologia et Immunopathologia)
Source: Allergologia et Immunopathologia - March 9, 2024 Category: Allergy & Immunology Authors: Victoria Villalobos Viol án Beatriz Gonz ález Cano Miguel Ángel Racionero Casero Elo ína González-Mancebo Esther Mohedano Vicente Mar ía Jesús Trujillo Trujillo Mar Gandolfo-Cano Source Type: research
Real-life experience after 3 months with tezepelumab before marketing approval
CONCLUSIONS: In this preliminary real-world experience prior to the official approval of tezepelumab in Spain, this monoclonal antibody showed promising results and suggests its potential as a valuable alternative for the treatment of severe asthma.PMID:38459894 | DOI:10.15586/aei.v52i2.1063 (Source: Allergologia et Immunopathologia)
Source: Allergologia et Immunopathologia - March 9, 2024 Category: Allergy & Immunology Authors: Victoria Villalobos Viol án Beatriz Gonz ález Cano Miguel Ángel Racionero Casero Elo ína González-Mancebo Esther Mohedano Vicente Mar ía Jesús Trujillo Trujillo Mar Gandolfo-Cano Source Type: research
Real-life experience after 3 months with tezepelumab before marketing approval
CONCLUSIONS: In this preliminary real-world experience prior to the official approval of tezepelumab in Spain, this monoclonal antibody showed promising results and suggests its potential as a valuable alternative for the treatment of severe asthma.PMID:38459894 | DOI:10.15586/aei.v52i2.1063 (Source: Allergologia et Immunopathologia)
Source: Allergologia et Immunopathologia - March 9, 2024 Category: Allergy & Immunology Authors: Victoria Villalobos Viol án Beatriz Gonz ález Cano Miguel Ángel Racionero Casero Elo ína González-Mancebo Esther Mohedano Vicente Mar ía Jesús Trujillo Trujillo Mar Gandolfo-Cano Source Type: research
Real-life experience after 3 months with tezepelumab before marketing approval
CONCLUSIONS: In this preliminary real-world experience prior to the official approval of tezepelumab in Spain, this monoclonal antibody showed promising results and suggests its potential as a valuable alternative for the treatment of severe asthma.PMID:38459894 | DOI:10.15586/aei.v52i2.1063 (Source: Allergologia et Immunopathologia)
Source: Allergologia et Immunopathologia - March 9, 2024 Category: Allergy & Immunology Authors: Victoria Villalobos Viol án Beatriz Gonz ález Cano Miguel Ángel Racionero Casero Elo ína González-Mancebo Esther Mohedano Vicente Mar ía Jesús Trujillo Trujillo Mar Gandolfo-Cano Source Type: research
Real-life experience after 3 months with tezepelumab before marketing approval
CONCLUSIONS: In this preliminary real-world experience prior to the official approval of tezepelumab in Spain, this monoclonal antibody showed promising results and suggests its potential as a valuable alternative for the treatment of severe asthma.PMID:38459894 | DOI:10.15586/aei.v52i2.1063 (Source: Allergologia et Immunopathologia)
Source: Allergologia et Immunopathologia - March 9, 2024 Category: Allergy & Immunology Authors: Victoria Villalobos Viol án Beatriz Gonz ález Cano Miguel Ángel Racionero Casero Elo ína González-Mancebo Esther Mohedano Vicente Mar ía Jesús Trujillo Trujillo Mar Gandolfo-Cano Source Type: research
